Global Top 10 Pharmaceutical Companies - Industry, Financial and SWOT Analysis

Introduction

This report analyzes the global pharmaceutical market in terms of market size, key drivers and resistors, trends and competitive positioning. It includes profiles of the top ten companies in the industry along with 5-year financial analysis and in-depth SWOT analysis.

Scope

*Performance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five years

*Obtain descriptive profiles of the top ten leading players including strategic initiatives undertaken in the last 12 months

*Analysis of the Strengths, Weaknesses, Opportunities and Threats of the top 10 pharmaceutical companies along with business overview and financials

*Benchmark the performance of the top 10 players for the past five years; includes revenue comparison, profitability analysis, industry-specific ratios

Highlights

The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.

The cardiovascular segment was the market's most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market's overall value.

The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.

Reasons to Purchase

*Save time, money and resources on analyzing the top 10 pharmaceutical companies using this report

*Analyze the global pharmaceutical market with key industry metrics including market value, market volume, and growth forecasts

*Assess the intensity of competition based on the 5-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power


Report Highlights
The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.

The cardiovascular segment was the market's most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market's overall value.

The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.
[Studien Infos ausblenden]

Table of Contents 2
FIGURES 3
Tables 4
Executive Summary 5
Industry analysis 5
Industry definition 5
Research highlights 5
Top 10 companies landscape 5
Market value 7
Market forecast 8
Market segmentation-product 9
Market segmentation-geographic 10
Five Forces Analysis 11
Summary 11
Buyer power 12
Supplier power 13
New entrants 14
Substitutes 15
Rivalry 16
Top 10 Companies Landscape 17
Overview 17
Pfizer 18
GlaxoSmithKline 18
F, Hoffmann-La Roche 19
Novartis 19
Sanofi-Aventis 19
AstraZeneca 19
Abbott Laboratories 19
Merck & Co. 19
Wyeth 20
Bristol-Myers Squibb Company 20
Revenue analysis 21
Financial performance analysis 23
Operating profit analysis 24
Net profit analysis 25
Ratio analysis 26
Company Reports 28
Pfizer Inc 28
Company overview 28
Business description 28
SWOT analysis 29
Strengths 29
Weaknesses 29
Opportunities 30
Threats 31
Recent developments 32
GlaxoSmithKline Plc 34
Company overview 34
Business description 34
SWOT analysis 35
Strengths 35
Weaknesses 36
Opportunities 37
Threats 38
Recent developments 38
F. Hoffmann-La Roche 40
Company overview 40
Business description 40
SWOT analysis 41
Strengths 41
Weaknesses 41
Opportunities 42
Threats 43
Recent developments 43
Novartis 45
Company overview 45
Business description 45
SWOT analysis 46
Strengths 46
Weaknesses 47
Opportunities 47
Threats 48
Recent developments 48
Sanofi-Aventis 50
Company overview 50
Business description 50
SWOT analysis 50
Strengths 50
Weaknesses 52
Opportunities 53
Threats 54
Recent developments 55
AstraZeneca 57
Company overview 57
Business description 57
SWOT analysis 58
Strengths 58
Weaknesses 59
Opportunities 60
Threats 62
Recent developments 62
Abbott Laboratories 64
Company overview 64
Business description 64
SWOT analysis 65
Strengths 65
Weaknesses 66
Opportunities 67
Threats 67
Recent developments 68
Merck & Co., Inc. 70
Company overview 70
Business description 70
SWOT analysis 71
Strengths 71
Weaknesses 71
Opportunities 72
Threats 74
Recent developments 74
Wyeth 77
Company overview 77
Business description 77
SWOT analysis 78
Strengths 78
Weaknesses 78
Opportunities 79
Threats 79
Recent developments 79
Bristol-Myers Squibb Company 82
Company overview 82
Business description 82
SWOT analysis 83
Strengths 83
Weaknesses 84
Opportunities 84
Threats 85
Recent developments 86
Five Year Financial Information 88
Pfizer 88
GlaxoSmithKline 91
F. Hoffman-La Roche 94
Novartis 97
Sanofi-Aventis 100
AstraZeneca 103
Abbott Laboratories 106
Merck & Co. 109
Wyeth 112
Bristol-Myers Squibb Company 115
APPENDIX 118
List of Tables
Table 1: Global pharmaceutical market, $ billion, 2004-2008 7
Table 2: Global pharmaceuticals market forecast, $ billion, 2008-2013 8
Table 3: Global pharmaceuticals market segmentation-product , % share 2008* 9
Table 4: Global pharmaceuticals market segmentation-geography, % share 2008* 10
Table 5: Revenues of global top 10 pharmaceutical companies, $ million, FY2008 17
Table 6: Revenue growth of global top 10 pharmaceutical companies, 2006-2008 21
Table 7: Key financials of global top 10 pharmaceutical companies, FY2008 23
Table 8: Key industry specific ratios-FY2008 26
Table 9: Pfizer-Financial and operational highlights, 2004-2008 ($ million) 88
Table 10: Pfizer-Key industry specific ratios, 2004-2008 90
Table 11: GlaxoSmithKline-Financial and operational highlights, 2004-2008 ($ million) 91
Table 12: GlaxoSmithKline-Key industry specific ratios, 2004-2008 93
Table 13: F. Hoffman-La Roche-Financial and operational highlights, 2004-2008 ($ million) 94
Table 14: F. Hoffman-La Roche-Key industry specific ratios, 2004-2008 96
Table 15: Novartis-Financial and operational highlights, 2004-2008 ($ million) 97
Table 16: Novartis-Key industry specific ratios, 2004-2008 99
Table 17: Sanofi-Aventis-Financial and operational highlights, 2004-2008 ($ million) 100
Table 18: Sanofi-Aventis-Key industry specific ratios, 2004-2008 102
Table 19: .Part (1) AstraZeneca-Financial and operational highlights, 2004-2008 ($ million) 103
Table 20: Part (2) AstraZeneca-Financial and operational highlights, 2004-2008 ($ million) 104
Table 21: AstraZeneca-Key industry specific ratios, 2004-2008 105
Table 22: Part(A) Abbott Laboratories-Financial and operational highlights, 2004-2008 ($ million) 106
Table 23: Part(B) Abbott Laboratories-Financial and operational highlights, 2004-2008 ($ million) 107
Table 24: Abbott Laboratories-Key industry specific ratios, 2004-2008 108
Table 25: Merck & Co.-Financial and operational highlights, 2004-2008 ($ million) 109
Table 26: Merck & Co.-Key industry specific ratios, 2004-2008 111
Table 27: Wyeth-Financial and operational highlights, 2004-2008 ($ million) 112
Table 28: Wyeth-Key industry specific ratios, 2004-2008 114
Table 29: Bristol-Myers Squibb Company-Financial and operational highlights, 2004-2008 ($ million) 115
Table 30: Bristol-Myers Squibb Company-Key industry specific ratios, 2004-2008 117
List of Figures
Figure 1: Global pharmaceuticals market, $ billion, 2004-2008 7
Figure 2: Global pharmaceuticals market forecast, $ billion, 2008-2013 8
Figure 3: Global pharmaceuticals market segmentation-product, % share 2008* 9
Figure 4: Global pharmaceuticals market segmentation-geography, % share 2008* 10
Figure 5: Forces driving competition in the global pharmaceuticals market 11
Figure 6: Drivers of buyer power in the global pharmaceuticals market 12
Figure 7: Drivers of supplier power in the global pharmaceuticals market 13
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market 14
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market 15
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market 16
Figure 11: Revenues of global top 10 pharmaceutical companies, $ million, FY2008 18
Figure 12: Revenue growth of global top 10 pharmaceutical companies, 2006-2008 22
Figure 13: Operating performance analysis, FY2008 24
Figure 14: Net profit analysis, FY2008 25
[Inhaltsverzeichnis ausblenden]